RTP-based Amphora Discovery Corporation (www.amphoracorp.com) has completed a $20 million Series C financing. The round was led by 3i Group, with new investors including Novartis Venture Fund and Aventis Capital. Existing investors ARCH Venture Partners, MPM Capital, Venrock Associates and Versant Ventures also participated in the round.
The company hopes to use the funds to speed up preclinical development of its drug candidates while also furthering drug discovery efforts with its partners. Amphora is focused on pathway-based drug using a highly industrialized approach. The company has preclinical drug candidates in the oncology and inflammation areas.
Amphora Discovery Corporation is a CED Member.